Skip to main content
IDWeek 2021 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
View Session ViewAttendees 8
Symposium

85 - Public-private partnerships to revive future antibiotic development and access

Friday, October 1, 2021
11:30 AM - 12:45 PM EDT

    Moderator(s)

  • Yohei Doi, MD, PHD

    Professor of Medicine
    Division of Infectious Diseases
    University of Pittsburgh
    Pittsburgh, PA, United States

    Astellas (Individual(s) Involved: Self): Grant/Research Support; AstraZeneca (Individual(s) Involved: Self): Speakers' bureau; bioMerieux (Individual(s) Involved: Self): Consultant, Speakers' bureau; Chugai (Individual(s) Involved: Self): Consultant; Entasis (Individual(s) Involved: Self): Consultant; FujiFilm (Individual(s) Involved: Self): Advisor or Review Panel member; Gilead (Individual(s) Involved: Self): Consultant; GSK (Individual(s) Involved: Self): Consultant; Kanto Chemical (Individual(s) Involved: Self): Grant/Research Support; MSD (Individual(s) Involved: Self): Speaking Fee; Pfizer (Individual(s) Involved: Self): Grant/Research Support; Shionogi (Individual(s) Involved: Self): Grant/Research Support, Speakers' bureau; Teijin Healthcare (Individual(s) Involved: Self): Speakers' bureau; VenatoRx (Individual(s) Involved: Self): Consultant

  • Prabhavathi Fernandes, PhD

    GARDP SAC Chair
    GARDP
    Chapel Hill, NC, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

    • Speaker(s)

  • Manica Balasegaram, BMBS, DTM&H, MSc, FRCP

    Executive Director
    GARDP, Switzerland

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

  • Mark Albrecht, PhD

    Chief
    Antibacterials Branch/BARDA/HHS

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

  • Sinead Delany-Moretlwe, MBBCh PhD

    Director: Research
    Wits RHI, University of the Witwatersrand
    Johannesburg, Gauteng, South Africa

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

Participants should be aware of the following financial/non-financial relationships:
Yohei Doi, MD, PhD: Astellas (Individual(s) Involved: Self): Grant/Research Support; AstraZeneca (Individual(s) Involved: Self): Speakers' bureau; bioMerieux (Individual(s) Involved: Self): Consultant, Speakers' bureau; Chugai (Individual(s) Involved: Self): Consultant; Entasis (Individual(s) Involved: Self): Consultant; FujiFilm (Individual(s) Involved: Self): Advisor or Review Panel member; Gilead (Individual(s) Involved: Self): Consultant; GSK (Individual(s) Involved: Self): Consultant; Kanto Chemical (Individual(s) Involved: Self): Grant/Research Support; MSD (Individual(s) Involved: Self): Speaking Fee; Pfizer (Individual(s) Involved: Self): Grant/Research Support; Shionogi (Individual(s) Involved: Self): Grant/Research Support, Speakers' bureau; Teijin Healthcare (Individual(s) Involved: Self): Speakers' bureau; VenatoRx (Individual(s) Involved: Self): Consultant
Prabhavathi Fernandes, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Manica Balasegaram, BMBS, DTM&H, MSc, FRCP: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Mark Albrecht, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Sinead Delany-Moretlwe, MBBCh PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-21-001-H01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:
  • define the barriers to new antibiotic development
  • list examples of public-private partnership in the area
  • describe approaches in ensuring access to essential antibiotics

Presentations:

  • Accelerating Development and Access of Critical Antibiotics: The Non-profit Model

    Speaker: Manica Balasegaram, BMBS, DTM&H, MSc, FRCP – GARDP

  • Catalyzing Antibiotic Development with Non-Dilutive Funding

    Speaker: Mark Albrecht, PhD – Antibacterials Branch/BARDA/HHS

  • Implementing a PPP Clinical Trial

    Speaker: Sinead Delany-Moretlwe, MBBCh PhD – Wits RHI, University of the Witwatersrand